Created by on 12/3/2010 12:00:00 AM

The NIH Scientific Management Review Board (SMRB), a panel established by the 2006 NIH reauthorization bill, is expected to formally recommend the creation of a new IC for translational research. The proposal to create a translational research IC was part of the draft recommendations made by the Translational Medicine and Therapeutics Working Group (TMAT WG), a subset of the SMRB composed of seven IC Directors and senior members of the scientific community.
The new IC would be composed of the Clinical and Translational Research Awards (CTSA) program, currently part of the National Center for Research Resources (NCRR), along with translational research and resources programs from the Office of Director: the Molecular Libraries Program, Therapies for Rare and Neglected Diseases, Rapid Access to Interventional Development, new NIH-FDA partnership programs, and the recently created Cures Acceleration Network. The draft recommendations do not address several key issues what will happen to NCRR’s remaining programs. 
The TMAT WG recommendations are scheduled to be voted on at the December 7, 2010 SMRB meeting. Once formal recommendations have been made by the SMRB, the NIH Director may accept them and issue a more detailed proposal to the Secretary of the Department of Health and Human Services. If the Secretary approves, she must notify Congress, which then has 180 days to reject the recommendations. FASEB will be considering the TMAT recommendations at its December 6th Board Meeting, and FASEB President, William Talman, MD, will attend the TMAT public meeting.